Trials / Terminated
TerminatedNCT00423150
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
A Phase 2 Study of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is proposed to evaluate the efficacy and safety of temozolomide, an oral anti-cancer agent, in a participant population selected for a biomarker. Participants with colorectal cancer, non-small-cell lung cancer, head and neck cancer, or esophageal cancer will be included.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Temozolomide | Temozolomide capsules 150 mg/m\^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent. |
Timeline
- Start date
- 2007-01-26
- Primary completion
- 2009-06-11
- Completion
- 2009-06-11
- First posted
- 2007-01-18
- Last updated
- 2017-06-08
- Results posted
- 2010-07-05
Source: ClinicalTrials.gov record NCT00423150. Inclusion in this directory is not an endorsement.